BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at Citizens Jmp

BeOne Medicines (NASDAQ:ONC) had its price target upped by Citizens Jmp from $405.00 to $463.00 in a research report report published on Friday morning,Benzinga reports. They currently have a market outperform rating on the stock.

A number of other research analysts have also recently weighed in on ONC. Wells Fargo & Company boosted their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday. JPMorgan Chase & Co. lifted their price target on shares of BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a report on Thursday, October 1st. Royal Bank Of Canada lifted their price target on shares of BeOne Medicines from $450.00 to $459.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Finally, Wolfe Research reissued an “outperform” rating and set a $370.00 price objective on shares of BeOne Medicines in a report on Monday, August 10th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $434.79.

BeOne Medicines Stock Performance

Shares of NASDAQ:ONC traded up $19.71 during midday trading on Friday, reaching $406.96. The company had a trading volume of 941,725 shares, compared to its average volume of 364,122. The company’s 50 day moving average price is $363.49 and its 200 day moving average price is $326.34. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. The stock has a market cap of $44.68 billion, a P/E ratio of 51.71 and a beta of 0.63. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $410.71.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating the consensus estimate of $2.34 by $1.30. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. As a group, sell-side analysts anticipate that BeOne Medicines will post 8.99 EPS for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other news, insider Titus B. Ball sold 132 shares of BeOne Medicines stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total value of $46,973.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 54,892 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the sale, the chief executive officer owned 240,743 shares in the company, valued at approximately $86,222,105.45. This represents a 18.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 376,373 shares of company stock worth $134,848,154. Company insiders own 6.19% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. Sanders Morris Harris LLC purchased a new position in shares of BeOne Medicines during the third quarter worth approximately $1,134,000. Renaissance Technologies LLC bought a new position in shares of BeOne Medicines in the first quarter worth approximately $19,438,000. Rokos Capital Management LLP bought a new position in BeOne Medicines in the 1st quarter valued at approximately $4,256,000. SEB Asset Management AB bought a new stake in BeOne Medicines in the 1st quarter worth about $16,653,000. Finally, Generali Investments Management Co LLC bought a new stake in shares of BeOne Medicines in the second quarter worth approximately $2,280,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.